Malignant Melanoma: Update Bulletin [April 2016]

Malignant Melanoma: Update Bulletin [April 2016]

Code: FW-21072016-23 | Published: Apr-2016 | Pages: 0 | FirstWord
Price :
$995.00
USD

* Required Fields

$995.00

Details

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF status; Philogen’s pivotal Phase III trials for Darleukin and Fibromun in patients with stage IIIB/C melanoma and the prospects of Provectus Biopharmaceuticals’ PV-10 in Phase III trial are also discussed.

Will Opdivo plus Yervoy combination therapy use increase significantly following BRAF V600 (wild-type & mutation-positive) label expansion?
Which patient subsets do KOLs think will benefit most from Opdivo plus Yervoy combination?
What are KOLs expecting from the two year survival data in CheckMate 069?
How successful do KOLs think Philogen’s Darleukin and Fibromun immunocytokines will be in melanoma?
What safety concerns do KOLs have with Darleukin/Fibromun and which combinations could hold the key to their success?
What are the prospects of Provectus’ PV-10 and how do KOLs view the inclusion of Imlygic as a comparator in Phase III study?

Table of Contents


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients